| Document |
Document Title |
|
WO/2004/014851A2 |
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a co...
|
|
WO/2004/012649A2 |
The invention relates to novel macro cyclenes of formula (I), a method for the production thereof and the use thereof for in-vivo stimulation of nerve growth, the in-vivo inhibition of scar tissue formation and/or in-vivo reduction of se...
|
|
WO/2004/009530A1 |
A process for the production of compounds represented by the general formula (3) and having high purity: (3) [wherein R1 is C1-6 alkyl or the like and R2 is hydrogen or the like, or R1 and R2 may be united to form C1-6 alkylene; and R3 a...
|
|
WO/2003/105832A1 |
The invention relates to the use of nefopam for the manufacture of a medicament for the treatment of nausea, dizziness, blurred vision and emesis.
|
|
WO/2003/105833A1 |
(+)-Nefopam is formulated for intranasal administration, for use in the treatment of pain.
|
|
WO/2003/101490A1 |
A drug composition comprising a calcium channel antagonist exhibiting intestinal tract selectivity that is used for treating Alzheimer disease, mental illness, adolescent insanity, manic depression, migraine, lactation disorder, dementia...
|
|
WO/2003/097618A1 |
Compounds of formula (I'): (I); wherein: R1 represents substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; X represents -(CRkaRkb)k-; Rka and Rkb are each independently hydrogen or C1-6alkyl; k is 0-5; Y represe...
|
|
WO/2003/095434A1 |
The present invention provides a compound which has 5-HT6 receptor affinity of the formula (I): a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Z1, m, n, and p are as defined herein. ...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/076424A1 |
The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders...
|
|
WO/2003/070254A1 |
This invention features a compound of the following formula (I): wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agen...
|
|
WO/2003/068980A2 |
Provided is a method for obtaining a macrolide, especially tacrolimus, from biomatter.
|
|
WO/2003/043618A2 |
The present invention relates to the treatment of Alzheimer's disease and other similar diseases, and more specifically to the use of compounds that inhibit beta-secretase, an enzyme that cleaves amyloid precursor protein to produce A be...
|
|
WO/2003/024941A1 |
Naphthalene compounds represented by the general formula (1) or pharmaceutically acceptable salts, hydrates or solvates thereof, which exhibit anti−HIV activity and are useful in the treatment of AIDS: (1) wherein each symbol is as def...
|
|
WO/2003/016245A1 |
The present invention is directed to the separation of enantiomers of racemates of formula (I). The separation proceeds by applying deemed racemates to continuos enantioselective chromatography like SMB. The methods predominantly is perf...
|
|
WO/2003/002147A1 |
Preventives&sol remedies for organ functional disorders, preventives&sol remedies for organ dysfunction and preventives&sol remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its ...
|
|
WO/2003/000670A1 |
The present invention provides novel compounds of Formula (I). The invention further relates to pharmaceutical compositions comprising compounds of Formula I and to methods of using compounds of Formula I to treat neuropsychiatric disord...
|
|
WO/2002/100392A1 |
The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs o...
|
|
WO/2002/100347A2 |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
|
WO/2002/096891A1 |
A dihydrodiaryloxazepine derivative represented by the following formula [I] or an analogue thereof&semi and a medicinal composition containing either. These compounds are highly effective in alleviating functional digestive tract diseas...
|
|
WO/2002/080928A1 |
Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
|
|
WO2001057015A9 |
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into op...
|
|
WO/2002/069895A2 |
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate rece...
|
|
WO/2002/060870A2 |
Methods and pharmaceutical compositions for the treatment of pain, preferably with lowered risk of induction of seizure in a patient. The compositions contain active compounds that are tricyclic $g(d) opioid receptor agonists of the gene...
|
|
WO/2002/057218A1 |
The present invention relates to alanine 2,6-dialkoxyphenyl ester derivatives having the general formula I, Formula (I) wherein R¿1? is (C¿1-3?)alkyloxy, (C¿1-3?)alkyloxy(C¿1-3?)alkyl, (C¿1-3?)alkylthio, (C¿1-3?)alkylthio(C¿1-3?)a...
|
|
WO/2002/051838A1 |
The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes f...
|
|
WO/2002/051232A2 |
The invention relates to novel benzazepines and related heterocyclic derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for t...
|
|
WO/2002/046167A1 |
The present invention relates to compounds of the formula I wherein 1) Y is a bridge containing bridging heteroatoms and to their medicinal use; 2) As serotonin 1 (5-HT¿1?) receptor ligands, particularly in psychotherapeutic agents.
|
|
WO/2002/044139A1 |
The invention concerns compounds of formula (I), wherein: A is a group of formula (a) or (b), their salts or solvates, pharmaceutical compositions containing them, a method for preparing them and intermediates used in said method. The co...
|
|
WO/2002/038180A1 |
A novel high-density lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect.
|
|
WO/2002/034705A2 |
A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a car...
|
|
WO/2002/026723A1 |
There are provided according to the invention, novel compounds of formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, X a, b, and Z are as defined in the specification, processes for preparing them, formulations containing them...
|
|
WO/2002/026724A1 |
A compound having general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds. The compounds are Neurokinin 1 (NK¿1?) receptor antagonists and are useful...
|
|
WO/2002/024204A2 |
The invention provides compositions and methods for altering insulin secretion using an agent that inhibits calcium efflux via the mitochondrial calcium/ sodium antiporter (MCA). Methods of treatment are thereby provided, and are particu...
|
|
WO/2002/022572A2 |
One aspect of the present invention relates to heterocyclic compounds formula A; whereof the substituents are defined in the description. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligand...
|
|
WO/2002/023541A1 |
Zofimarin derivatives having an excellent antifungal activity, and pharmacologically acceptable esters and pharmacologically acceptable salts thereof; medicinal compositions (in particular, antifungal agents) containing the same as the a...
|
|
WO/2002/010144A1 |
The invention relates to an improved method for preparing 7,16-deoxy-2-aza-10-O-cladinosil-12-O-desosaminil-4,5-dihydr
oxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle[11.2.1]hexa-dec
a-1(2)-en-8-ona from erythromycin A, wherein said compoun...
|
|
WO/2002/000626A1 |
Compounds according to general formulae (1 and 2), wherein G?1¿ is an azepine derivative and G?2¿ is a group according to general formulae (9 - 11) are new. Compounds according to the invention are vasopressin V¿2? receptor agonists. ...
|
|
WO/2001/098282A1 |
There is disclosed a compound represented by formula (I), wherein R?1¿ is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X?1¿-X?2¿-Ar...
|
|
WO2000009509A9 |
A process for synthesizing 4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazatetracyclo-[5.5.0.0
<5,9>0<3,11>]-dodecane ("TEX") involves combining at least one hexa-substituted piperazine derivative with a medium containing at least one nitronium...
|
|
WO/2001/092226A1 |
One aspect of the present invention relates to novel heterocyclic compounds, such as Formula (1). A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, ...
|
|
WO/2001/090082A1 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula (1) wherein one of X, Y, or Z is independently -S-, -O-, or > N-R?4¿, the others are-CH¿2-;? (p) is an i...
|
|
WO/2001/090081A1 |
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula (I) wherein one of X, Y or Z is independently -S-,-0- CH¿2?- or $m(g)N-R?6¿, the others are -CH¿2?-; m ...
|
|
WO/2001/077089A1 |
A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
|
|
WO/2001/060820A2 |
Thus the present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase ...
|
|
WO/2001/055118A1 |
Benzene-fused heterocycle derivatives of the general formula (I); and nontoxic salts thereof (wherein each symbol is as defined in the description). The compounds of the general formula (I) exhibit inhibitory activities against cysteine ...
|
|
WO/2001/029005A1 |
Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH¿2?, O and N-alkyl, Z is either S or -CH=CH-, R?1¿ and R?2¿ are independently selected...
|
|
WO/2001/017980A1 |
Industrially advantageous processes for preparing 5-substituted-5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives through intramolecular arylation and reduction from [2-(2-bromobenzyloxy)phenyl]amide derivatives bearing via amide linkage...
|
|
WO/2001/004103A1 |
Compounds of formula (I), as well as pharmaceutically usable salts and esters thereof, wherein R?1¿, R?2¿, X, Y, Z and p have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types...
|
|
WO/2000/071518A2 |
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate rece...
|
